ClinicalTrials.gg
Status unknownNCT00959868Updated Feb 13, 2012

A Study for Treatment of Superficial Bladder Cancer Using OGX-427

A Phase 1 interventional study of OGX-427 in Bladder Cancer, sponsored by Vancouver Coastal Health. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-13.

Sponsored by Vancouver Coastal Health · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Urinary Bladder Neoplasms with a site in Canada — 32 open to participants now, 59 under way, 21 of them phase 3. Urinary Bladder Neoplasms · Canada.

Planned enrollment
112th of 135
36 · median 154
Started
2009
the only one that year
Phase 1
18 of 153
3 open now
Registered
35th of 153
by date

Among the 153 studies in Urinary Bladder Neoplasms with a site in Canada, this one is the 112th largest by planned enrollment of the 135 interventional ones that give a count, is the only one that started in 2009, is one of 18 in phase 1, and was the 35th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

32 of the 153 studies in Urinary Bladder Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Urinary Bladder Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a single centre, open label, phase I dose escalation trial using a modified accelerated titration design. Patients with superficial bladder tumour (Ta or T1) or CIS and candidates for transurethral resection or muscle invasive disease (>T2) and candidates for radical cystectomy will be enrolled.

OGX-427 will be given neoadjuvantly over 8 days, followed by a transurethral resection (for superficial disease) or radical cystectomy (for muscle invasive disease).

Baseline Hsp27 levels will be determined from pre-treatment cytological samples from bladder washings and tumour biopsies performed prior to therapy.

Post-treatment PK and PD data will be determined from TUR (for Ta, T1 tumours) or radical cystectomy (for T2 tumours) specimens. A recommended phase II dose will be determined from the toxicity, tissue pK, and percentage of Hsp27 knockdown. Effects of treatment on Hsp27 client protein levels and apoptotic index will also be evaluated.

Evaluation during protocol treatment will take place to assess toxicity. Assessments will occur on various visits as per Evaluation Schedule. Adverse event evaluation based on NCI CTCAEv3.0. For quality of life assessment during treatment, the EORTC QLC-BLS24 will be used before first treatment (day 1) and prior to surgery (TURBT or radical cystectomy). The Day 1 QOL assessment will serve as baseline.

After removal from protocol treatment, all subjects will be followed for toxicity related to study drug for 30 days.

After the study, subjects will be followed according to standard of care. Follow-up for tumour recurrence or superficial tumours will be assessed every three months by cystoscopic examination for two years, then every six months for the next two years, and then yearly thereafter.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Bladder cancer
  • Superficial bladder cancer (Ta or T1)
  • Muscle invasive bladder cancer (T2)
  • Transurethral resection
  • Radical cystectomy
  • OGX-427
  • Antisense oligonucleotide
  • Heat shock protein 27
  • superficial bladder tumour (Ta or T1) or CIS prior to a transurethral resection
  • Muscle invasive (T2) bladder cancer prior to radical cystectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age must be > 18
  2. Histologic evidence of bladder cancer (superficial or muscle invasive) or

    CIS as evidenced by:

    • Patients presenting with superficial tumours and unknown pathological stage will have in-clinic bladder washings (performed cystoscopically) and (cup biopsy).
    • Patients with recurrent superficial disease (Ta or T1) and tissue that is available for baseline studies (i.e. tissue from previous transurethral resection stored in paraffin blocks) will be eligible for trial without requiring cytology or biopsy.

      • Patients with previously diagnosed T1 tumours and requiring re-resection of bladder tumour will be eligible if tissue from the original TURBT is available for baseline studies.
      • Patients presenting as muscle invasive (>T2) disease will be eligible if they are candidates for radical cystectomy and if baseline tissue from initial resections is available for baseline studies
  3. No intravesical therapies within the previous 6 months
  4. No evidence of disease as determined by physical exam, CT scan or chest- x-ray, where indicated.
  5. status must be 0, 1, or 2
  6. Laboratory requirements (within 7 days of treatment):

    • negative urine cultures
    • Absolute neutrophils count> 1.5 x 109 cells/L, and count> 100 x 109/L,
    • Total \< 1.5 x upper normal limit (), and/or ALT \< 1.5 x ULN, alkaline phosphatase \< 1.5 x ULN, and serum creatinine \< 1.5 x ULN.
    • and INR, within normal limits
  7. Patient must be able to complete the quality of life questionnaires in either English or French
  8. Patients must provide written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with "indeterminate" or "negative" results from or cytology will be ineligible for the trial.
  2. Patients taking warfarin or Coumadin anticoagulation therapy or who have a bleeding disorder. NOTE: Patients who require anticoagulation therapy while on study will be removed from study treatment.
  3. Pregnant or lactating women
  4. Patients not accessible for follow-up
  5. Patients with an active urinary tract infection, upper tract urothelial tumors, active infection including tuberculosis, concurrent febrile illness or impaired immune response from any cause
  6. Patients with to spinal or general anesthesia required for a transurethral resection or radical cystectomy
  7. Recent (\<14 days) urethral trauma or inability to perform catheterization or cystoscopy safely
  8. Patients known to have a serious illness or medical condition that would impair protocol treatment delivery.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Interventions

  • DrugApatorsenStudies of ApatorsenApatorsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.

06

What researchers measure

Primary outcomes

  1. To define the maximum tolerated dose (MTD) of OGX-427 administered as an intravesical instillation.

    The study medication will be escalated according to a fixed dose escalation plan. Three subjects will be treated per cohort. If one of the three subjects experiences a DLT, three additional subjects will be treated at that dose level (i.e. maximum of 6 subjects per cohort)

    Time frame: One year

  2. To define the dose-limiting toxicities (DLTs) of OGX-427 administered as an intravesical instillation.

    The study medication will be escalated according to a fixed dose escalation plan. Three subjects will be treated per cohort. If one of the three subjects experiences a DLT, three additional subjects will be treated at that dose level(i.e. maximum of 6 subjects per cohort)

    Time frame: one year

Secondary outcomes

  1. To determine the toxicity profile of OGX-427 when administered intravesically.

    Time frame: One year

  2. To measure evidence of OGX-427 effect on expression of Hsp27.

    Time frame: one year

  3. To determine the bladder PK and PD profile of OGX-427 after intravesical administration.

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • The Prostate Centre at Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
    • Maureen Palmer, RN · ContactMaureen.Palmer@vch.ca · 604-875-5675
    • Alan I So, MD, FRCSC · Principal investigator
    • Peter C Black, MD, FRCSC · Sub investigator
    • Edward C Jones, MD, FRCPC, LMCC · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009 and a primary completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2009
First posted
Aug 17, 2009
Start
Jul 2009
Primary completionEst.
Dec 2012
Last update
Feb 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00959868
Lead sponsor
Vancouver Coastal Health
Collaborators
NCIC Clinical Trials Group, Vancouver General Hospital Foundation
First posted
Aug 17, 2009
Start date
Jul 2009
Primary completion
Dec 2012 (estimated)
Last update
Feb 13, 2012

Study contacts

Maureen Palmer, RN
Contact
Maureen.Palmer@vch.ca
604-875-5675
Alan I So, MD, FRCSC
principal investigator · Vancouver Coastal Health

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatorsen

Start the discussion